

INDEX

- Absorption, *see* Chapter 13
atypical, 357–358
first-order, 351, 368
mixed first and zero order, 352, 355, 374
parallel, 352, 353, 372
variability, 347
Weibull-type, 352, 356, 376
zero-order, 352, 370
- Absorption models, *see* Chapter 13
- Adverse events or effects, 11–15, 205, 347, 633–636, 699, 763–765, 770, 773, 782, 939–942, 978, 1176–1177, 1182
- Analysis plan, *see* Chapter 11; pages 427, 428, 432, 434, 636, 818, 909–914, 922
- Antibodies, *see* Chapter 41
- Appropriateness
model, 10, 11, 209, 223–225, 414, 429
- Bayesian analyses, *see* Chapter 5; pages 6, 17, 104, 170, 247, 252, 273, 276, 408, 830, 834, 836, 1078
informative priors, *see* Chapter 5
noninformative priors, *see* Chapter 5
study designs, *see* Chapters 30 and 31
- Binary outcomes modeling, *see* Chapter 24; pages 169, 255, 466–469, 704, 767, 770, 773, 791–792, 892, 1182–1183, 1187
- Bioavailability, *see* Chapters 13, 16, 41; pages 3, 12, 15, 57, 65, 269, 665, 666, 883, 1085, 1101, 1165, 1166
- Bioequivalence, *see* Chapter 16
- Biological agents, *see* Chapter 41; pages 807, 809, 956
antibodies, 1018–1020
covariates
age, 1009
drug interactions, 1008–1009
liver function, 1009
patient characteristics, 1008
race, 1010
receptor number, 1007
renal function, 1009
sex, 1010
weight, 1008
cytokines, 1012
erythropoietin, 1016–1018
G-CSF, 1014–1016
growth factors, 1013–1014
interferons, 1013
model based pharmacodynamics, 1020–1025
programs for, 1021–1024
model based pharmacokinetics of
absorption, 1006–1007
clearance, 1007
pharmacodynamics of proteins, 1010–1011
covariates, 1020
proteins, *see* Chapter 45; pages 993–1005
absorption, 1003–1004
apparent volume of distribution of, 1004–1005
Brambell receptors, 1002
clearance, 998–1002
cytokines, 1002
humanization, 996–997
hyperglucosylation, 998
PEGylation, 997–998
production of, 996
- Biomarker, *see* Chapters 17 and 47; pages 1, 2, 4, 5, 7, 12, 16, 478, 549–550, 560, 571, 700, 794, 804, 816, 838–839, 877, 881–884, 921, 955, 957, 966, 977, 1011, 1012, 1021, 1024, 1025
biological activity marker, 458
clinical endpoint, 459
drug activity marker, 458
natural history markers, 458
validation of, 459
surrogate endpoint, 2, 4, 5, 16, 245, 458, 794, 960, 966
validation of, 459–463
Type 0 marker, 458
Type I marker, 458
Type II marker, 458

- Biophase, 529–539, 588, 607–608, 617, 661, 811
 Biosignal, 511–521, 530, 535, 608, 620, 624–625
 Bootstrap, *see* Chapters 14, 15, 16; pages 226, 231, 233, 236, 237, 249, 252, 255, 295, 476, 480, 734, 750, 751, 754, 831, 834, 836, 885, 888, 984, 1036, 1041, 1043, 1044, 1046, 1049, 1061, 1079, 1080
 Bayesian, 408
 bias estimates from, 409–410
 comparing nonhierarchical models from, 412
 confidence intervals from, 409
 double, 408
 estimating inestimable standard errors from, 412–413
 model building from, 411–412
 nonparametric, 405
 optimism, 410–411
 parametric, 407
 prediction error estimates from, 410–411
 residuals, 407
 smoothed, 407
 standard, 405
 standard estimates from, 408
- Categorical data
 nonordered, 693–695
 Markov model and, 693–695
 ordered, *see* Chapter 25
 survival, 656–660
 two step, 668–669
 skewness and, 668–670
- Cell trafficking, 510
- Clinical trial simulation, *see* Chapters 33, 34, 35; pages 5, 7, 16, 291, 312, 315, 384, 457, 576, 770, 822, 830–832, 916, 970
 elements of, 854–858
- Clustering, 390–391, 723, 1176, 1186
 genomic microarrays, *see* Chapter 18
- Communication of model results, *see* Chapter 37; pages 210, 287, 289–290, 298–300, 387, 832–833, 873, 918, 922, 1183
 graphical display
 effectiveness, 928
 excellence, 931–932
 framework, 928–931
 integrity, 932
 graphics
 decomposition, 927
 graphics for, 926–932
 information integration, 932–933
 information processing, 926–927
 knowledge integration, 932–933
 perception, 928
 qualitative, 927
 quantitative, 927
 retinal image, 927
- Compliance, *see* Chapter 6
 modeling, *see* Chapter 6
 Bayesian objective function, 170
 hierarchical Bayesian, 170
 likelihood, 169–170
 Markov, *see* Chapter 6
 maximum penalized marginal likelihood (MPML), 171
 missing design history, 170
 probabilistic model, 169
- Computer codes
 ADAPT, *see* Appendix 12.1
 buy or build, 61
 Matlab, 37, 40
 NONMEM, *see* Chapters 21 and 28; Appendices 7.1–7.3, 13.1–13.6, 16.1, 22.1, 24.1–24.3, 25.1, 25.2, 25.5, 27.1, 30.1, 35.1, 44.1, 45.1; pages 395, 555–559, 562, 565, 707, 727–32, 736, 1021–1023, 1112
 PERL, 338–339
 S-Plus, *see* Chapters 3 and 4; Appendices 4.1, 9.1, 12.2, 12.8, 16.1, 25.1, 25.3–25.6, 32.1–32.3, 42.1–42.6; pages 436, 692
 UNIX, *see* Appendices 12.4, 12.6
 validation, 61
 WinBUGS, 158–159
 WinNonLin, *see* Appendix 22.1; pages 257, 495, 629–631, 1077
- Computer programs
 ADAPT, 26, 59, 307, 309–310, 327–331, 495, 523, 1077
 buy or build, 61
 Matlab, 26–49, 143, 308, 859, 864, 1070, 1076, 1079, 1081, 1084, 1087, 1091
 NONMEM, *see* Chapter 28; Appendices 13.1–13.6, 16.1, 22.1, 24.1–24.3, 25.1, 25.2, 25.5, 27.1, 30.1, 35.1, 45.1; pages 26, 54, 59, 66, 184, 189–199, 218–219, 228, 236, 274–275, 277–280, 293, 295–296, 307, 310–311, 318, 320, 332–342, 392, 395, 417, 433, 437, 554–568, 573, 638, 640–641, 663, 864, 1021–1024, 1077, 1112
 PERL, 338–339
 R, 31
 S, 31
 S-Plus, *see* Chapter 4; Appendices 3.1, 4.1, 9.1, 12.2, 12.8, 16.1, 25.1, 25.3–25.6, 32.1–32.3, 42.1–42.6; pages 26, 30–33, 48, 59, 66, 70, 72–73, 75–76, 78, 80–87, 89–95, 97, 187, 277, 297, 308, 393, 837, 864–865, 991
 UNIX, 335, 337
 validation, 61
 WINBUGS, *see* Chapter 5; pages 104, 274
 WinNonLin, 54, 67, 257, 584, 600–603, 629, 864, 1077
 WinNonMix, 59, 67, 945, 950, 1077
 Xpose, 5, 298, 393

- Computer programming
 - debuggers, 32
 - extreme programming, *see* XP approach
 - good practices
 - coding, 33–36
 - constructs, 33–36
 - syntax, 33–36
 - mathematical concepts, 36–38
 - absolute differences, 38
 - equality and inequality issues, 37–38
 - machine precision, 36–37
 - operator precedence, 36
 - overflow, 38
 - relative differences, 38
 - underflow, 38
 - modular code design, 44–46
 - reducing errors, 38–41
 - script and program design, 41–43
 - software development life cycle, 61, 67
 - software and engineering, 48–50
 - steps in, 28
 - tasks, 26–27
 - writing extensible and noniterative programs, 46–48
 - XP approach (extreme programming), 50
- Computer software
 - repository systems
 - Matlab, 32, 67
 - Octave, 31, 1076
 - user required specification, 59–64
 - validation, 53–103
 - ANSI, 55
 - IEEE, 55
 - installation qualification, 70–74
 - operation qualification, 75–86
 - performance qualification, 86–102
 - PKBugs, 145
 - process, 62
 - qualification, 64
 - system specification, 63
 - WinBugs, 140
- Confidence intervals, 214, 219–222
- Covariates
 - approaches for inclusion in models, *see* Chapters 8 and 14
 - percentile division, 1177
 - selection of, *see* Chapters 8 and 14
 - time varying covariates, 394
- Cross-validation, *see* Chapters 8 and 15
 - k-fold or grouped, 404
 - leave-one-out, 404
- Cytokines, 1012
- D-optimality, 307–312, 792
- Data
 - censored, *see* Chapter 25; pages 254–255, 868
 - collection, *see* Chapter 11; pages 9, 15, 293, 440, 794, 914, 920
 - real-time, 2, 14, 15, 293, 295, 875, 879
 - count, *see* Chapter 25
 - description of types of incomplete, 246
 - imputation, *see* Chapter 9
 - ordered categorical, *see* Chapter 25
 - reducing data, 296
 - set construction of, 293–294
 - survival, 656–660
- Deconvolution, 350, 1160–1161, 1169
- Disease progression, *see* Chapter 21
 - models
 - asymptotic, 560–569
 - data pooling and, 550–551
 - Gompertz, 570
 - inverse Bateman, 566–569
 - linear, 553–560, 579
 - transit, 571–574
- Distributions
 - Bernoulli, 635, 704
 - Poisson, 701–710, 719–720
 - uniform, *see* Chapter 9
 - Wishart, 140, 146, 151, 854
 - zero inflated Poisson (ZIP), 704–710, 719–720
- Dose escalation, 460, 669–670, 725, 762, 783–784, 792–794, 982, 1035
- Dose proportionality, 57, 104–110, 118, 269, 762–777, 1035
- Drug-drug interaction, 14, 266, 303, 317–319, 346, 362, 959, 994, 1076
- Drug safety, *see* Chapter 47
- Effects, therapeutic, beneficial, 536. *See also* Adverse events or effects
- Enterohepatic recycling, *see* Chapter 13; page 380
- Epistemology, *see* Chapter 8
- Erythropoietin, 1016–1018
- Exploratory data analysis, 636–639
- Exposure response regulatory considerations, 807–812
- Exposure-response relationship, *see* Chapters 31 and 38; pages 8, 634, 639, 643–644, 700–701, 710–717, 770, 797, 830, 882–883, 1182–1187
 - applications of, 939–948
 - area under the curve, 8, 12, 422, 639, 643, 706, 767, 773, 775, 792, 812, 931, 1004, 1122, 1137, 1180–1187
 - for dose selection, 940
 - maximum concentration, 8, 13, 149, 157, 350, 586, 1003, 1180–1182
 - minimum concentration, 8, 13
 - programs for, 950–953
 - understanding the E-R relationship, 938–939

- Exposure response studies, *see* Chapters 31 and 38
- Bayesian adaptive dose allocation, 822–823
 - concentration controlled trials, 823–824
 - crossover designs, 104, 126, 266, 421–426, 438–439, 445, 725, 761–764, 767–769, 775–777, 795, 814–816, 886–887, 959, 981–983, 1159, 1167
 - flexible designs, 820
 - group sequential designs, 820–822
 - parallel group designs, 665, 735, 812–814, 887, 981, 982
 - titration designs, 783, 824–825
- First time in humans (FTIH) studies, *see* Chapters 29 and 30; pages 14, 830, 873
- adverse events in, 763, 767, 771–774, 777–778
 - cohort size, 762–763
 - dose escalation scheme, 762, 766–769
 - Fibonacci, 762, 766–769, 783, 793–794
 - oncology in, *see* Chapter 30
 - accelerated titration in, 785
 - Bayesian designs in, 787
 - combination of two drugs, 795–796
 - continual reassessment in, 787–790
 - data collection in, 794–795
 - decision theoretic approach in, 791–792
 - dose escalation in, 783–784, 792–794
 - escalation with overdose control, 790–791
 - isotonic regressions in, 786
 - random walk rules, 785–786
 - study designs, 762, 765–769
 - efficiency of, 763, 770, 772
- Fisher information matrix, 150, 307, 308, 310
- Food and Drug Administration
- Guidance for Industry
 - critical path, 1–2, 288, 547, 761, 811, 881, 905, 937
 - exposure response, 7, 807
 - pediatric pharmacokinetics, 956
 - population pharmacokinetics, 7, 291, 304
- G-CSF, 1014–1016
- Gene expression, *see* Chapters 18 and 19
- microarrays, *see* Chapter 18
 - polymerase chain reaction, 474–475, 510, 517
- Generalized additive modeling (GAM), *see* Chapter 14; pages 230, 411, 836, 1176, 1177
- Genomics, *see* Chapters 18 and 19
- Genomic marker, modeling, 511–512
- Gibb's sampling, 141–142
- Good clinical practice, 55
- Good laboratory practice, 55
- Goodness-of-fit, *see* Graphics, goodness-of-fit
- Graphics, *see* Chapter 7
- after model development, 209–214
 - box and whisker plots, 200, 257, 342, 343, 388, 737, 738, 773, 930, 931, 1042
 - box plots, *see* box and whisker plots
 - data checkout plots, 189–192, 294, 299
 - data exploration plots, 192–193
 - excellence in, 931–932
 - goodness-of-fit, 195–198, 203, 206, 229, 234
 - during model development, 193–209
 - multipanel, 187, 188, 206, 213, 930
 - QQ plots, 192, 196, 199
 - partial residual plots, 389–390
 - plots of residuals, 198, 199, 389, 390
 - population modeling and, *see* Chapter 7
 - smooths, 967
 - cubic splines, *see* Chapter 20; page 280
 - locally weighted (LOESS), 186
 - splines, *see* Chapter 20; page 280
 - tree plots or models, 479, 480, 484, 838, 1176, 1180, 1181
 - trellis, 105, 111, 116, 687, 688
 - visualizing effect of individualized dosing, 212
 - visualizing relative effect of covariates to explain variability, 211
 - whisker plots, *see* box and whisker plots
- Growth factors, 1013–1014
- Hazard function (rate), *see* Chapter 25; pages 466, 890
- Weibull, *see* Chapter 25; pages 861
- Information technology
- infrastructure, 56, 61
 - organization, *see* Chapter 3
- Interoccasion variability, 109, 118, 192, 200, 203, 229, 266, 270, 279, 281, 303, 315, 853, 967
- Imputation of data, *see* Chapter 9; pages 386, 394, 434, 661, 833, 983
- multiple imputation, *see* Chapter 9
 - conditional, 255
 - for truncated data, 254
 - Markov chain Monte Carlo, 252
 - nonparametric Bayesian, 252
 - parametric Bayesian, 251
 - propensity adjusted, 254
 - software for, 259
 - single imputation, 247–249
 - hot deck, 248
- Interferons, 1013
- Information theory
- for interoccasion variability, 315
 - sample size and power, 315
 - samples for drug-drug interaction, 317
 - samples per subject, 314
 - and sampling, 305–313
 - empirical, 306

- D-optimality, 307–312, 792
 Fisher information matrix, 150, 307–314, 334–341
 informative block randomized, 308–341
- In vitro in vivo correlations, *see* Chapter 46; pages 610, 793–794, 852, 881, 1000, 1002, 1024, 1070, 1074–1075, 1150
 convolution based, 1161–1162
 correlation levels
 level a, 1059–1162
 level b, 1158
 level c, 1158–1159
 deconvolution in, 1160–1161
 predictability from, 1162–1165
- Jack-knife, *see* Chapter 15; pages 226, 236, 237, 393, 481, 984
- Knowledge creation, *see* Chapters 32 and 47; pages 2, 10, 16–17
 data synthesis, 830, 1176
 clinical trial simulation, 830–832
 physiologically based pharmacometric model, 831
 data supplementation, 10, 830–838, 840–842, 1176, 1188
 procedure, 833–835
 methods, 833
 estimating inestimable standard errors from, 831
 missing data and, 394. *See also* Imputation of data
 process, 831
 structure based multiple supplementation, 835–840
- Knowledge discovery, *see* Chapters 14 and 47, pages 2, 9–10, 232, 241, 829–836, 841–843
 high dimensionality and, 393–394
 missing data and, 394. *See also* Imputation of data
 steps of, 384–385
 techniques of
 clustering, 389
 generalized additive modeling, 388
 partial residual plot, 390
 tree based model, 391
 time varying covariates, 394
- Learn-confirm-learn process, 7–10, 14–15, 548, 781, 805, 905
- Likelihood profile, 226, 295, 445, 446, 453
- Logistic regression, *see* Chapter 24; pages 169, 255, 466–469, 704, 767, 770, 773, 791–792, 892, 1184–1185, 1189
- Log-odds, 662
- Markov chain, 167–169, 252, 274, 689–693, 856.
See also Markov chain Monte Carlo
 assumptions of, 692–693
 discrete time, 690–692
 first-order, 691–692
 second-order, 692
 hybrid mixed effects and proportional odds, 694–696
- Markov chain Monte Carlo, 46, 104, 140, 158, 252, 274, 428, 1077
- Medication event monitoring system (MEMS), *see* Chapter 6
- Metabolism, *see* Appendix 43.5; pages 317, 345, 465, 614, 725, 881, 956, 965, 978, 1081–1082, 1107–1109
- Metabolites, *see* Chapter 44
- Metropolis-Hastings algorithm, 141, 142, 252
- Microarray, *see* Chapters 18 and 19
 application of, 497–498
 data analysis, 475–497
 clustering, 477
 gene function, 483–484
 model based approaches, 488–489
 unsupervised, 478
 modeling of profiles, 517–522
 simple regulated genes, 518–522
- Mixture model, *see* Chapter 28; pages 158–161, 171, 228, 564–565, 883, 1151
 dynamic mixtures, 735–739
 kurtosis and, 726, 732, 736, 750
 skewness and, 726, 729–732, 736, 750
 hypothesis testing, 733–735
 multiple mixtures, 740–743
 parameterization and
 probability, 731–732
 submodel, 725–731
- Mixture modeling, *see* Chapter 28; pages 158–161
- Model(s)
 appropriateness, 10, 11, 209, 223–225, 414, 429
 biomarker-outcomes link, 2, 1183
 credible, 224–225
 circadian, 537–538, 589, 983–984
 covariate, 200–201, 292, 295, 394, 426–427, 433, 709–710, 720, 854, 884, 967–970
 descriptive, 1, 9, 10, 226, 240, 401, 831, 894, 1176
 development, *see* Chapters 8, 11, 14; pages 2, 9, 10, 14, 143, 183, 294 403–406, 414, 433, 496, 751, 912, 914, 915, 962, 1111, 1113, 1138
 disease progression, *see* Chapter 21
 asymptotic, 560–569
 data pooling and, 550–551
 Gompertz, 570

- Model(s) (*Continued*)
- inverse Bateman, 566–569
 - linear, 553–560, 579
 - transit, 571–574
 - evaluation, *see* Chapter 8; pages 153, 405, 751, 1078, 1087
 - identification, 227–233
 - goodness of fit, 195–198, 203, 206, 229, 234
 - reliability, *see* Chapter 8
 - stability, *see* Chapter 8; pages 391, 396, 438
 - log-odds, 662
 - mixture, *see* Chapter 28; pages 158–161, 171, 228, 564–565, 883, 1151
 - dynamic, 735
 - graphics and, 743–749
 - multiple, 740
 - simulations and, 750–754
 - nonhierarchical, 232–233, 405, 412
 - pain relief, 662–663, 886
 - pharmacodynamic, 713–714
 - empirical, *see* Chapter 20
 - genomics and, *see* Chapter 19
 - mechanistic, *see* Chapters 22 and 23
 - ordered categorical longitudinal, *see* Chapter 25
 - pharmacokinetic, *see* Chapter 43; pages 394, 415, 665, 866, 1005, 1111
 - pharmacokinetic-pharmacodynamic, *see* Chapters 11, 19, 20, 22, 23, 24, 25; pages 5, 16, 111–112, 114, 466, 468, 792, 794, 804, 855
 - empirical, *see* Chapter 20
 - indirect response, *see* Chapters 22 and 23; pages 6, 466, 512, 561, 567, 571, 662, 866, 1010
 - mechanistic, *see* Chapters 22 and 23; pages, 4, 477, 495, 510, 515, 808, 815, 852, 853, 877, 882, 883, 1012, 1019, 1142
 - pharmaco-statistical, 811
 - population, 240, 266, 425, 435, 439, 467, 842, 969, 1114
 - predictive, 10, 226, 401, 696
 - proportional odds, 656, 689, 691, 694–696, 792, 1187
 - qualification, 224–225
 - remedication, 663, 886
 - semiparametric, 537
 - survival, *see* Chapter 25
 - time to event, *see* Chapter 25; pages 466, 790
 - tolerance, *see* Chapters 20 and 23; pages 790–791
 - transition, *see* Chapter 26
 - mixed effects, 693–694
 - types of
 - base, 316, 432, 433, 640–642, 698, 712, 714, 966, 967, 971, 972, 1114
 - descriptive, 10, 226, 401, 696
 - full, 46, 148, 229–233, 316–319, 390, 412, 836, 885, 890, 1114, 1118, 1125
 - predictive, 1, 9, 10, 226, 240, 401, 831, 894, 1176
 - validation, *see* Chapter 8; pages 401, 402, 497, 916, 943
 - internal, 237, 401, 405, 406, 497, 1171
 - external, 237, 241, 401, 916
 - metrics of, *see* Chapter 8
 - predictive performance in, 153, 156, 237, 240, 385, 410, 751, 1162
 - verification, 224–225
- Model comparison, 412, 1144–1151
- hierarchical, *see* Chapter 5; 229–233, 414, 971, 1113, 1138
 - objective function and, 642, 971, 1113
 - nonhierarchical, 232–233, 405, 412, 642
- Model selection
- Bayesian, *see* Chapter 5; pages 153–156, 170
 - nonhierarchical, 232, 233, 405
- Modeling
- biomarkers and, 465–466
 - communication of results, *see* Chapter 37; pages 210, 287, 289–290, 298–300, 387, 832–833, 873, 918, 922, 1183
 - efficiency, *see* Chapter 11; pages 295, 324
 - initial parameter estimates, 296, 497
 - long run times, 295
 - metabolites, *see* Chapter 44
 - microarrays, 475–497
 - physiologically based, *see* Chapter 43; page 349
 - using time between runs, 297–298
- Modeling and simulation, *see* Chapters 33, 34, 35; pages 118–119, 123, 317, 815, 903–906, 913, 917, 920–922, 947, 1172
- applying the results of, 879
 - clinical trials, 7, 226, 241, 258, 303–305, 309, 312, 315–319, 351–352, 383–384, 442–443, 457, 467, 489, 575–576, 586–587, 591–595, 700, 770, 797, 815, 822–824, 929–931, 947, 970, 984, 1075, 1138
 - example of, 889–894
 - elements of, 854–858
 - execution of plan, 878, 888–889
 - program code for, 896–900
 - project evaluation, 874
 - project plan and planning, 876–878, 882
 - model based input factors, 882–886
 - output responses, 887
 - simulation team review, 887–888
 - trials based input factors, 886–887
 - project resources, 875
 - timelines and, 875, 879
- Monte Carlo simulation, *see* Chapters 33, 34, 35; pages 28, 46, 158, 307, 403, 409, 442, 466, 468, 469, 962, 969, 1078

- Nelfinavir, *see* Chapter 44
- Noncompartmental analysis, 257, 259, 346, 432, 435, 961
- Nonhierarchical models, *see* Models
- Nonlinear models and modeling, *see* Chapter 45; pages 266, 639, 994
- Northern blot, 510, 517
- Parallelization, 28, 31, 290, 294, 295, 298, 486, 927, 928
- Parameter estimation, *see* Chapters 8, 10, 12; pages 46, 171, 387, 426, 523, 669, 724, 776, 853, 929, 1070
- identifiability, 233–234
- reliability of, 305
- robustness of, 305
- Pediatrics
- clinical trial simulation in, 970
- contrasted to adults, 964–966
- covariate issues in, 966–968
- obstacles to pharmacometric research in, 958–964
- pharmacometrics in, *see* Chapter 39; pages 14, 15, 17, 118, 392, 401, 423, 563, 939
- sampling strategies in, 969
- Percentile division technique, 1177
- Pharmacodynamics
- definition, 4
- empirical models, *see* Chapter 20
- E_{\max} , 205, 208, 306, 438, 442, 466, 531–532, 558, 562, 565, 615, 711, 741, 819, 866, 940
- Hill equation, 466, 1171
- linear, 531
- sigmoid E_{\max} , 532, 533, 607, 616, 618, 819, 1016
- history of, 4
- indirect response models, *see* Chapters 22 and 23; pages 6, 466, 512, 561, 567, 571, 662, 866, 1010
- limitations of, 588–589
- irreversible effects, *see* Chapter 23; pages 588, 782
- agonism, 615–617
- cell proliferation, 583, 608–612, 1012
- enzymatic inactivation, 612–614
- reactive metabolites, 588, 614–616
- transduction, time dependent, 615–619
- transit compartment model, 617–619
- turnover model, 612–614
- ordered categorical longitudinal, *see* Chapter 25
- rebound, 270, 517, 619–623
- counter regulatory effect, 619–621
- mRNA up or down regulation, 621–622, 625
- precursor pool alteration, 622–623, 1011–1012
- receptor desensitization, 621
- receptor up or down regulation, 621–622
- tolerance, 487, 512, 517, 519, 540, 619–623, 790, 939, 947, 1012
- counter regulatory effect, 619–621
- mRNA up or down regulation, 621–622, 625
- precursor pool alteration, 622–623, 1011–1012
- receptor desensitization, 621
- receptor up or down regulation, 621–622
- transition, *see* Chapter 26
- viral dynamic models, 308, 589–596
- limitations of, 595–596
- Pharmacogenomics, *see* Chapter 19; page 495
- modeling methods, 523
- program for, 526–527
- Pharmacokinetics
- history, *see* Chapter 1
- population estimation methods, *see* Chapter 10
- Pharmacokinetic/Pharmacodynamic, link models, 5, 535–537
- Pharmacometric Enterprise, *see* Chapter 36
- Enterprise design, 917–922
- Enterprise process, 911–917
- generic, 907–909
- specific, 909–911
- systems engineering, 905–906
- Pharmacometrics
- definition, 2
- role in drug development, *see* Chapter 1
- Phase 1, *see* Chapters 29, 30, 31, 45; pages 12, 14–16, 266, 316, 349, 359, 361, 429, 460, 636, 1007, 1140
- Phase 2, *see* Chapters 31 and 45; pages 8, 15–17, 118, 241, 351, 636, 782, 784, 875, 879, 881–882, 889, 940, 947
- Phase 3, *see* Chapters 1, 31, 38; pages 118, 315, 350, 424, 468, 875, 889
- Phase 4, 6, 17, 460, 1109
- Physiologically based models, *see* Chapter 43; page 349
- implementation and evaluation, 1075–1079
- inhalation, 1072
- model formulation, 1071–1075
- model parameters, 1074–1075
- model structure, 1072–1074
- Polymerase chain reaction, 474–475, 510, 517
- Population modeling
- designing, 291
- efficiency and, *see* Chapter 11; page 324
- estimation methods, *see* Chapter 9
- Bayesian two-stage, 273–274
- Bayesian with Gibb's sampling, 274
- global two stage, 272–273
- iterative two-stage (IT2S), 273
- naïve average data approach, 269–270
- naïve pooled data analysis, 270, 523

- Population modeling (*Continued*)
 nonlinear mixed effects, 274–277
 nonparametric maximum likelihood, 278–279, 406
 semiparametric maximum likelihood, 279–280
 standard two stage, 272
 two stage, 14, 271, 818, 969
 planning, *see* Chapters 35 and 36; pages 2, 14, 289, 293
 plan writing for, 291
 Posterior predictive check, *see* Chapter 15; pages 156–158, 237–238, 401, 413–414, 750–753, 836, 1078
 Prediction intervals, 219–222
 Predictive performance, 153, 156–158, 237, 240, 385, 410, 751, 1162
 Profile likelihood, 226, 295, 445, 446, 453
 Proteins, *see* Biologicals
- QT interval, *see* Chapter 40; pages 2, 14, 466, 812, 883
 consideration in study design, 981–991
 automated data analysis, 990–991
 baseline ECG, 986
 dealing with outliers, 988–989
 endpoint for, 986–987
 maximum mean change, 987
 mean maximum change, 987
 number and timing of ECG recordings, 983–986
 number of subjects, 981–983
 placebo controls, 987–988
 positive controls, 987–988
 correction for heart rate, 979–981
- Quantic pharmacokinetics, *see* Chapter 42
- Random number generation, 29, 42, 241, 469, 657, 678–679, 858–860, 862, 899
- Receptor, binding, 481, 512, 514, 530, 615–617, 1141
- Regulatory process, agencies, 809, 906, 908, 937
- Reports
 computer programming, 27, 40, 47, 63
 pharmacometric, *see* Chapter 11; pages 644, 874, 876–879, 912, 917, 922
- Resampling methods and techniques, *see* Chapter 15; 237–238, 837, 984, 1036, 1039–1043, 1046, 1048
- Response surface, *see* Chapters 32 and 47; pages 8–10, 245, 251, 383–384, 391, 529, 548–551, 957, 1078
- Restricted maximum likelihood, 104, 277
- Scale up to humans, *see* Chapters 29 and 30; pages 14, 830, 873. *See also* First time in humans (FTIH)
- Sensitivity analysis, 152, 226, 385, 427, 858, 883, 1072, 1076
- Simulation, *see* Chapters 33, 34, 35; pages 27, 30, 33, 37–39, 47–48, 113, 115, 118, 146, 148, 151, 156, 160, 170–177, 185, 203, 206, 209, 212, 222, 256, 258, 271, 303–309, 404, 413, 441, 461, 489, 575, 586, 587, 591–595, 611, 621–625, 664, 667, 669, 725, 735, 750, 770, 830–832, 903–905, 909, 913, 920–922, 931, 1078–1079, 1084, 1087
 clinical trials, 5, 7, 226, 241, 258, 291, 303–305, 309, 312, 315–319, 351–352, 383–384, 442–443, 457, 467, 489, 575–576, 586–587, 591–595, 700, 770, 788, 797, 815, 822–824, 929–931, 947, 963, 970, 984, 1075, 1138
 continuous variables, 861–863
 discrete variables, 863–864
 program codes, 113, 119, 122–123, 333–337, 369–382, 678–679, 752–753
 software, 2, 5, 30, 257, 811, 843–848, 1076, 1077
 efficacy trials, *see* Chapter 35
 planning and execution, *see* Chapter 34
 theory, *see* Chapter 33
 stochastic, Monte Carlo, *see* Chapters 33, 34, 35; pages 7, 28, 48, 158, 307, 403, 409, 442, 466, 468, 469, 962, 969, 1078
- Software
 acslXtreme PK/PD toolkit, 1076
 ADAPTII, 1077
 Berkeley Madonna, 1077
 BUGS, 1077
 buy or build, 61
 ERDEM, 1076
 Gastro-Plus, 1076
 GNUOctave, 1076
 Matlab, 26–49, 143, 308, 859, 864, 1070, 1076, 1079, 1081, 1084, 1087, 1091
 MCSim, 1077
 ModKine, 1076
 NONMEM, 1077
 Pharmacokinetic/Pharmacodynamic modeling, 59–67, 104, 112, 114
 PKQuest, 1076
 PK-Sim, 1076
 R, 31
 S, 31
 S-Plus, 30–31
 Simcyp, 1076
 STELLA, 1077
 validation, 61
 WinSAAM, 1076
- Smooths, 967
 cubic splines, *see* Chapter 20; page 280
 locally weighted (LOESS), 186
 splines, *see* Chapter 20; page 280

- Stirling's formula, 707
- Studies, first time in man, *see* Chapters 29 and 30; pages 14, 830, 873. *See also* First time in humans (FTIH)
- phase 1, *see* Chapters 29, 30, 31, and 45; pages 12, 14–16, 266, 316, 349, 359, 361, 429, 460, 636, 1007, 1138
- phase 2, *see* Chapters 31 and 45;
 pages 8, 15–17, 118, 241, 351, 636, 782, 784, 875, 879, 881–882, 889, 940, 947
- phase 3, *see* Chapters 1, 31, 38; pages 118, 315, 350, 424, 468, 875, 889
- phase 4, 6, 17, 460, 1109
- preclinical, 14, 149, 787
- Surrogate endpoint, *see* Chapter 17; pages 2, 4–5, 16, 794, 960, 966
- Therapeutic effect, *see* Chapters 31 and 35; pages 8, 536
- Time to event data or model, *see* Chapter 25; pages 466, 790
- Tissue to plasma ratio, *see* Chapter 42
- comparison of estimation method, 1042–1047
- estimation of, 1036–1042
- naïve averaging, 1038
- naïve averaging program, 1050–1051
- pseudoprofile-based bootstrap, 1041
- pseudoprofile-based bootstrap program, 1055–1057
- random sampling, 1039–1041
- random sampling program, 1051–1055
- Toxicokinetics, 1035
- Tree based modeling (TBM), 213, 231, 385, 387, 391, 838, 839, 1176, 1180, 1181
- Validation
- model, *see* Model
- computer program, *see* Computer program
- metrics, *see* Model validation
- Wishart distribution, 146, 148, 151
- ZIP distribution, 704, 706

